Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management

Evangelos Triantafyllou; Cathrin L C Gudd; Lucia A Possamai

doi:10.1038/s41575-024-01019-7

Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management

Nat Rev Gastroenterol Hepatol. 2024 Dec 11. doi: 10.1038/s41575-024-01019-7. Online ahead of print.

Authors

Evangelos Triantafyllou¹, Cathrin L C Gudd², Lucia A Possamai^{3

4}

Affiliations

¹ Section of Hepatology and Gastroenterology, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom. e.triantafyllou@imperial.ac.uk.
² Section of Hepatology and Gastroenterology, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
³ Section of Hepatology and Gastroenterology, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom. l.possamai@imperial.ac.uk.
⁴ Liver and Antiviral Unit, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom. l.possamai@imperial.ac.uk.

PMID: 39663461
DOI: 10.1038/s41575-024-01019-7

Abstract

Immunotherapy has changed the treatment landscape for patients with cancer in the past decade. Immune checkpoint inhibitor (ICI)-based therapies have proven effective in a range of malignancies, including liver and gastrointestinal cancers, but they can cause diverse off-target organ toxicities. With the increasingly wider application of these drugs, immune-mediated liver injury from ICIs has become a commonly encountered challenge in clinical hepatology and gastroenterology. In this Review, we discuss the evidence from human and animal studies on the immunological mechanisms of immune-mediated liver injury from ICIs and summarize its clinical features and practical considerations for its management.

Publication types

Review